Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study
- 12 February 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 127 (6), 673-680
- https://doi.org/10.1161/circulationaha.112.124248
Abstract
Background—: We sought to evaluate the effect of potent platelet inhibition after acute coronary syndrome on total (ie, first and recurrent) occurrences of any of the primary outcome events (eg, cardiovascular death, myocardial infarction, and stroke) as well as on other ischemic events, such as urgent revascularization, (severe) recurrent ischemia, transient ischemic attacks, and arterial thrombotic events. Methods and Results—: In the PLATelet inhibition and patient Outcomes (PLATO) study, 18 624 patients presenting with acute coronary syndromes randomly received ticagrelor (n=9333) or clopidogrel (n=9291). Cox proportional hazard models were used to calculate time to first event and hazard ratios. Total events were compared using a Poisson regression model, and time to second event or death was calculated with the Wei Lin Weissfeld method. Patients randomized to ticagrelor had 1057 total primary end point events versus 1225 for patients on clopidogrel (rate ratio, 0.86; 95% confidence interval, 0.79–0.93; P =0.003). The number of additional events was numerically lower for ticagrelor (189 versus 205; P =0.40), resulting in a hazard for time to second event/death of 0.80 (95% confidence interval, 0.70–0.90; P P P =0.01) and a highly significant concurrent reduction in hazard for time to second event or death of 0.83 (95% confidence interval, 0.75–0.91; P P =0.96 and 0.38, respectively). Conclusions—: In PLATO, treatment with ticagrelor compared with clopidogrel resulted in a reduction in total events, including first and subsequent recurrent cardiovascular events, when compared with clopidogrel. These types of analyses demonstrate an even greater absolute benefit of ticagrelor over clopidogrel than previously reported. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov/ . Unique identifier: NCT00391872.This publication has 12 references indexed in Scilit:
- Comparison of 80 versus 10 mg of Atorvastatin on Occurrence of Cardiovascular Events After the First Event (from the Treating to New Targets [TNT] Trial)The American Journal of Cardiology, 2010
- Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary InterventionCirculation, 2010
- Total Cardiovascular Disease Burden: Comparing Intensive With Moderate Statin Therapy: Insights From the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) TrialJournal of the American College of Cardiology, 2009
- Reduction in Recurrent Cardiovascular Events With Intensive Lipid-Lowering Statin Therapy Compared With Moderate Lipid-Lowering Statin Therapy After Acute Coronary SyndromesJournal of the American College of Cardiology, 2009
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesThe New England Journal of Medicine, 2009
- Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trialEuropean Heart Journal, 2008
- Cost and Cost-effectiveness of an Early Invasive vs Conservative Strategy for the Treatment of Unstable Angina and Non–ST-Segment Elevation Myocardial InfarctionJAMA, 2002
- Cost-effectiveness of an invasive strategy in unstable coronary artery disease. Results from the FRISC II invasive trialEuropean Heart Journal, 2002
- Checking the Cox model with cumulative sums of martingale-based residualsBiometrika, 1993
- Regression Analysis of Multivariate Incomplete Failure Time Data by Modeling Marginal DistributionsJournal of the American Statistical Association, 1989